Survival of women with ovarian carcinomas and bord... - BV FAPESP
Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status

Full text
Author(s):
Sallum, Luis Felipe [1] ; Sarian, Luis Otavio [1] ; De Angelo Andrade, Liliana Lucci [2] ; Vassallo, Jose [3, 4, 5] ; Soares, Fernando Augusto [3] ; Pinto, Glauce Aparecida [5] ; Ferreira, Patricia Andreia [6] ; Derchain, Sophie [1]
Total Authors: 8
Affiliation:
[1] State Univ Campinas UNICAMP, Dept Obstet & Gynecol, Sao Paulo - Brazil
[2] State Univ Campinas UNICAMP, Fac Med Sci, Dept Pathol, Sao Paulo - Brazil
[3] Hosp Canc AC Camargo, Fundacao Antonio Prudente Sao Paulo, Dept Pathol, Sao Paulo - Brazil
[4] State Univ Campinas UNICAMP, CIPED, Dept Pathol, Lab Investigat & Mol Pathol, Campinas, SP - Brazil
[5] State Univ Campinas UNICAMP, CAISM, Lab Expt Pathol, Sao Paulo - Brazil
[6] State Univ Campinas UNICAMP, Fac Med Sci, Sao Paulo - Brazil
Total Affiliations: 6
Document type: Journal article
Source: JOURNAL OF GYNECOLOGIC ONCOLOGY; v. 24, n. 2, p. 167-176, APR 2013.
Web of Science Citations: 6
Abstract

Objective: To examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with ovarian carcinoma, in relation to ER and/or PR expression. Methods: We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based immunohistochemistry. Results: Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher in endometrioid tumors than in mucinous tumors (p<0.01). DES was affected neither by the clinical characteristics nor by combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and those with residual disease after surgery (p<0.01). Conclusion: Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression. (AU)

FAPESP's process: 09/18306-3 - Correlation between the expression of p53, Ki67, WT1, ²-catenin and hormone receptors in relation to morphological and clinical features of borderline and invasive epithelial ovarian tumors
Grantee:Patricia Andreia Rodrigues Ferreira
Support Opportunities: Scholarships in Brazil - Scientific Initiation